News

The American Indian and Alaska Native population show the largest increase in median state ratios, rising from 14 - 49.2, while the Black population consistently had the highest median state ratios, increasing from 26.7 - 55.4.

New phase 2 data indicates safety and efficacy of dersimelagon, suggesting potential development as an oral treatment for erythropoietic protoporphyria and X-linked protoporphyria.

A recap of the top news from the 83rd Scientific Sessions of the American Diabetes Association, including data related to retatrutide, tirzepatide, oral semaglutide, and more!

After adjusting for potential confounding factors, patients with microvascular diseases, particularly diabetic retinopathy, and diabetic kidney disease, were found to have a greater possibility of left ventricular hypertrophy.

Dr. Juliana Biondo discusses the exciting FDA approval of Roctavian and how it compares with other treatment options like Hemlibra.

Our June 2023 cardiology month in review includes 3 FDA approvals, a primary prevention subgroup analysis of CLEAR Outcomes, and a meta-analysis of 13 major trials examining SGLT2 inhibitor use.

While the FDA decision of Roctavian offers patients with hemophilia A more options, the gene therapy eligibility criteria still pose barriers.

This new data into alopecia areata patients’ associated conditions may require future research into potential causal relationships with such comorbidities.

Analysis of a novel form of the topical drug shows rosacea is benefitted within 2 weeks of daily administration.

Diabetic retinopathy and microalbuminuria were associated with a significantly higher risk of hemodialysis induction in individuals with T2D.

An analysis of 3 academic health centers suggests youth with diabetic retinopathy had a longer duration of diabetes and higher hemoglobin A1c at the time of the diabetic eye exam.

An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.

Juan Frias, MD, discusses the potential impact of an FDA approval for once-weekly insulin icodec based on data observed within the ONWARDS program.

New research on patients with pemphigus highlighted the heavy mental burden on those with these conditions and the importance of screening for anxiety, depression, and quality of life.

At ADA 2023, we asked interview guests for their opinions on the most important news to come from this year's scientific sessions, including Juan Frias, MD, Bob Gabbay, MD, PhD, Yehuda Handelsman, MD, Viral Shah, MD, and more.

New research into menopausal hormone therapy shows that even short term use can have downstream consequences for neurological health.

Pegozafermin was associated with improvements in fibrosis and could contribute to a resolution of NASH, according to the results of the phase 2b ENLIVEN trial.

A new analysis presented at ADA 2023 recommended effective diabetic retinopathy screening for patients with T2D and hypertension.

The data provide promising results, yielding a smoking abstinence rate of 26.4% in the intervention group at 18 months.

New research into the information needs of adults over 65 and their patient portal interactions points to the value of consumer-oriented health information technologies.

The approval is supported by positive results from the largest and longest phase 3 study for gene therapy in hemophilia, showing a 52% reduction in annualized bleeding rate compared with baseline rates on routine prophylaxis.

This quarter's issue highlights expert perspective on systemic and invasive care for gastric disease, the ELEVATE model, and fecal immunochemical testing for colorectal cancer.

A history of bariatric surgery was associated with up to 50% reduced risk of PDAC among a national cohort.

How an outpatient-based smoking cessation model may come to aid other health systems' gastroenterology patients.

Investigators assess the detection rate of FIT and FIT-DNA among average-risk colorectal cancer screening individuals.

The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.

Investigators from the TRANSITION-T2D study join Diabetes Dialogue to discuss the study and implications for care.